Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

STAAR Surgical to Report Third Quarter Results on November 3, 2016

STAAR Surgical Company
Posted on: 20 Oct 16

PR Newswire

MONROVIA, Calif., Oct. 20, 2016

MONROVIA, Calif., Oct. 20, 2016 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2016 on Thursday, November 3, 2016after the market close. 

STAAR will host a conference call and webcast on Thursday, November 3 at 4:30 p.m. Eastern / 1:30 p.m.Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 97993546), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Conference ID 97993546) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL." More than 600,000 Visian ICLs have been implanted to date. To learn more about the ICL go to:  www.discovericl.com.  STAAR has approximately 360 employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.

CONTACT:

Investors & Media                                        


EVC Group                                        


Brian Moore, 310-579-6199              


Doug Sherk, 415-652-9100                           

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/staar-surgical-to-report-third-quarter-results-on-november-3-2016-300348716.html

SOURCE STAAR Surgical Company

PR Newswire
www.prnewswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.